



SDI FINAL EVALUATION FORM 1.1

PART 1:

Journal Name:	<u>Journal of Advances in Medical and Pharmaceutical Sciences</u>
Manuscript Number:	Ms_JAMPS_29316
Title of the Manuscript:	Prevalence and antimicrobial susceptibility profile of bacteria isolated from the environment of two tertiary hospitals in Calabar metropolis, Nigeria
Type of Article:	Original Research Article

PART 2:

FINAL EVALUATOR'S comments on revised paper (if any)	Authors' response to final evaluator's comments
1. Although authors reply my comments in in SDI reviewer form 1.6, I cannot find any modified parts according to revised author's comments in revised manuscript. Authors should modify according reviewer's comment in revised manuscript if they reply. 2. I suggested such comments before: Antibiotics should be written in a generic name instead of the product name. 3. Authors reply that the antibiotics have been appropriately written in generic names. But, for example, ampiclox is commercial name because it contain both two antibiotics such as ampicillin and cloxacillin. Author should describe ampicillin and cloxacillin instead of Ampiclox. 4. I do not find any modification about my two suggestions; MICs and MBCs should be shown by the micro g/mL. How did authors calculate MAR indices? If authors cannot modify according to my comments, they should explain the reason.	

Reviewer Details:

Name:	<i>Anonymous</i>
Department, University & Country	<i>Nagoya City University, Japan</i>